Matches in SemOpenAlex for { <https://semopenalex.org/work/W2209511907> ?p ?o ?g. }
- W2209511907 endingPage "187" @default.
- W2209511907 startingPage "181" @default.
- W2209511907 abstract "Purpose The objective of this randomised phase II study was to evaluate the impact in terms of response and toxicities of induction or consolidation chemotherapy respectively before or after concurrent chemoradiotherapy in unresectable stage III non-small-cell lung cancer. Patients and methods In the induction arm, patients received induction chemotherapy with cisplatin (80 mg/m2) and paclitaxel (200 mg/m2) on days 1 and 29 followed by a concurrent chemoradiotherapy (66 Gy in 33 fractions, cisplatin 80 mg/m2 days 1, 29 and 57, vinorelbine 15 mg/m2 days 1, 8, 29, 36, 57 and 64). In consolidation arm, the same concurrent chemoradiotherapy began on day 1 followed by two cycles of cisplatin and paclitaxel. Results One hundred twenty seven patients were randomised. The intent to treat response rates in induction and consolidation arms were 58% and 56% respectively. Median survival was 19.6 months in induction arm and 16.3 months in consolidation arm and 4-year survival rates were 21% and 30% respectively. Haematologic and non-haematologic toxicities were similar in both arms, except grade 3/4 oesophagitis, more frequent in consolidation arm than in induction arm (17% versus 10%). Conclusion Cisplatin-based chemotherapy as induction or consolidation with concurrent chemoradiotherapy can be administrated safely. Response rates were similar in both arms with a trend in favour for consolidation arm for long-term survival." @default.
- W2209511907 created "2016-06-24" @default.
- W2209511907 creator A5001498932 @default.
- W2209511907 creator A5006393406 @default.
- W2209511907 creator A5007512072 @default.
- W2209511907 creator A5009365878 @default.
- W2209511907 creator A5009550163 @default.
- W2209511907 creator A5010033165 @default.
- W2209511907 creator A5010647689 @default.
- W2209511907 creator A5011586516 @default.
- W2209511907 creator A5015179583 @default.
- W2209511907 creator A5016370905 @default.
- W2209511907 creator A5016951491 @default.
- W2209511907 creator A5017481421 @default.
- W2209511907 creator A5018117609 @default.
- W2209511907 creator A5020293093 @default.
- W2209511907 creator A5020652734 @default.
- W2209511907 creator A5021741635 @default.
- W2209511907 creator A5021824422 @default.
- W2209511907 creator A5022125986 @default.
- W2209511907 creator A5022856335 @default.
- W2209511907 creator A5022986634 @default.
- W2209511907 creator A5023065527 @default.
- W2209511907 creator A5023471756 @default.
- W2209511907 creator A5024025993 @default.
- W2209511907 creator A5024880435 @default.
- W2209511907 creator A5025466073 @default.
- W2209511907 creator A5025597273 @default.
- W2209511907 creator A5027488058 @default.
- W2209511907 creator A5027601056 @default.
- W2209511907 creator A5027608149 @default.
- W2209511907 creator A5031298811 @default.
- W2209511907 creator A5031592033 @default.
- W2209511907 creator A5033220886 @default.
- W2209511907 creator A5034083299 @default.
- W2209511907 creator A5035989109 @default.
- W2209511907 creator A5036301038 @default.
- W2209511907 creator A5037249637 @default.
- W2209511907 creator A5039103158 @default.
- W2209511907 creator A5039623202 @default.
- W2209511907 creator A5040378408 @default.
- W2209511907 creator A5040513765 @default.
- W2209511907 creator A5040544006 @default.
- W2209511907 creator A5042971392 @default.
- W2209511907 creator A5043045128 @default.
- W2209511907 creator A5043692738 @default.
- W2209511907 creator A5043914694 @default.
- W2209511907 creator A5046596676 @default.
- W2209511907 creator A5047594386 @default.
- W2209511907 creator A5047686124 @default.
- W2209511907 creator A5048266187 @default.
- W2209511907 creator A5049089621 @default.
- W2209511907 creator A5050464038 @default.
- W2209511907 creator A5050744273 @default.
- W2209511907 creator A5050864299 @default.
- W2209511907 creator A5053842558 @default.
- W2209511907 creator A5054233620 @default.
- W2209511907 creator A5056164932 @default.
- W2209511907 creator A5056722255 @default.
- W2209511907 creator A5057308134 @default.
- W2209511907 creator A5059332845 @default.
- W2209511907 creator A5060112597 @default.
- W2209511907 creator A5061593805 @default.
- W2209511907 creator A5063103135 @default.
- W2209511907 creator A5063465326 @default.
- W2209511907 creator A5064408563 @default.
- W2209511907 creator A5065081920 @default.
- W2209511907 creator A5065135422 @default.
- W2209511907 creator A5065747611 @default.
- W2209511907 creator A5068135434 @default.
- W2209511907 creator A5068255952 @default.
- W2209511907 creator A5071671046 @default.
- W2209511907 creator A5072758102 @default.
- W2209511907 creator A5074273224 @default.
- W2209511907 creator A5075795161 @default.
- W2209511907 creator A5079214434 @default.
- W2209511907 creator A5083087091 @default.
- W2209511907 creator A5084083761 @default.
- W2209511907 creator A5084830410 @default.
- W2209511907 creator A5085436416 @default.
- W2209511907 creator A5086704496 @default.
- W2209511907 creator A5087836238 @default.
- W2209511907 creator A5088183082 @default.
- W2209511907 creator A5088910060 @default.
- W2209511907 creator A5090078704 @default.
- W2209511907 date "2016-01-01" @default.
- W2209511907 modified "2023-10-17" @default.
- W2209511907 title "Induction or consolidation chemotherapy for unresectable stage III non-small-cell lung cancer patients treated with concurrent chemoradiation: a randomised phase II trial GFPC – IFCT 02-01" @default.
- W2209511907 cites W1965825980 @default.
- W2209511907 cites W1981120866 @default.
- W2209511907 cites W1982331996 @default.
- W2209511907 cites W2029409133 @default.
- W2209511907 cites W2035704169 @default.
- W2209511907 cites W2038685153 @default.
- W2209511907 cites W2051534601 @default.
- W2209511907 cites W2060985892 @default.
- W2209511907 cites W2077123624 @default.
- W2209511907 cites W2084800358 @default.